Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.

Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate pharmaceutical compositions comprising such compounds methods of making and methods of using the same are disclosed.

Sustained release oral dosage forms of an

The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide preferably ziconotide in combination with an analgesic selected from the group consisting of morphine bupivacaine clonidine hydromorphone baclofen fentanyl buprenorphine and sufentanil or its pharmaceutically acceptable salts thereof wherein the omega-conopeptide retains its potency and is physically and chemically compatible with the ...

The present invention relates to combinations and methods for the treatment of macular degeneration disorders. More specifically, the present invention relates to novel combinatorial therapies of Age related Macular Degeneration based on baclofen and acamprosate combination.

594648 Disclosed herein is an oral tablet dosage form comprising a tablet and a coating, the tablet comprising: 3 wt-% to 20 wt-% (3R)-4-{ [(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy) carbonylamino} -3-(4-chlorophenyl)butanoic acid or a pharmaceutically acceptable salt thereof